Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535899 | 0.83 | KDM4E (0.51) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL29831982 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL3841616 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL8630313 | 0.79 | KDM4E (0.51) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL30081357 | 0.79 | MEN1 (0.44) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL2422282 | 0.79 | MEN1 (0.44) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL30288437 | 0.79 | KDM4E (0.51) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL2975427 | 0.77 | KDM4E (0.56) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL60874 | 0.75 | ALDH1A1 (0.61) | ALDH1A1KDM4EGAAHPGDSTAT3 | |
| SCHEMBL23970527 | 0.75 | TDP1 (0.44) | ALDH1A1KDM4EGAAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | US GOV VETERANS AFFAIRS (US) | 2023-04-27 | — | — | US | disclosed |
| US-8748388-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-06-10 | — | — | US | disclosed |
| EP-2046733-B1 | PROCESS FOR THE PREPARATION OF EPSILON-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES | ITALIANA SINT SPA (IT) | 2011-10-05 | — | — | EP | disclosed |
| US-8026372-B2 | Process for the preparation of ε-alkoxycarbonyllysines and their analogues | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| US-20090312557-A1 | PROCESS FOR THE PREPARATION OF EPSILON -ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2009-12-17 | — | — | US | disclosed |
| EP-2046733-A1 | PROCESS FOR THE PREPARATION OF EPSILON-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008014811-A1 | PROCESS FOR THE PREPARATION OF ε-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312557-A1 | PROCESS FOR THE PREPARATION OF EPSILON -ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES | AADAT, ALKBH3, BCAT2 | ALDH1A1 2475/4885KDM4E 77/4885GAA 1226/4885 |
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | BRCA1, MTPN, MUSK | ALDH1A1 4054/4885KDM4E 732/4885GAA 2637/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | ALDH1A1 319/4885KDM4E 4485/4885GAA 292/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | ALDH1A1 319/4885KDM4E 4485/4885GAA 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.